Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -387.97% | 39.47% | 138.28% | 117.57% | 103.20% |
| Total Depreciation and Amortization | -97.06% | -93.58% | -58.11% | -57.97% | -15.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.54% | -85.05% | -55.41% | -39.24% | -32.53% |
| Change in Net Operating Assets | 91.06% | 76.93% | -238.30% | -690.64% | -442.22% |
| Cash from Operations | 65.74% | 61.52% | 25.87% | 26.35% | 54.99% |
| Capital Expenditure | -- | -- | -- | 55.00% | 81.29% |
| Sale of Property, Plant, and Equipment | 71.63% | -- | -- | -- | 1,296.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.01% | -99.99% | 93.91% | -16.96% | -101.38% |
| Cash from Investing | 47.67% | -91.46% | 110.44% | -13.88% | -101.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 71.97% | 44.38% | 22.76% |
| Issuance of Common Stock | -52.44% | -62.02% | -72.84% | 366.58% | 353.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,288.33% | 99.99% | 85.71% | -170.80% | -96.76% |
| Cash from Financing | -82.54% | -44.69% | -72.85% | -74.19% | 101.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.01% | 73.52% | -1,958.45% | -122.80% | 0.19% |